Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Up to $27.88

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) gapped up prior to trading on Wednesday . The stock had previously closed at $27.88, but opened at $30.87. Supernus Pharmaceuticals shares last traded at $32.87, with a volume of 175,886 shares traded.

Supernus Pharmaceuticals Price Performance

The stock’s fifty day moving average price is $27.72 and its 200-day moving average price is $29.34. The firm has a market cap of $1.81 billion, a price-to-earnings ratio of -113.34 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.36. Supernus Pharmaceuticals had a negative net margin of 2.60% and a negative return on equity of 1.68%. The business had revenue of $168.30 million for the quarter, compared to analyst estimates of $148.83 million. During the same quarter in the previous year, the business earned ($0.02) earnings per share. The firm’s revenue was up 24.1% compared to the same quarter last year. As a group, equities research analysts predict that Supernus Pharmaceuticals, Inc. will post 1.31 EPS for the current fiscal year.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, insider Tillotson Martin Tami 2,900 shares of the business’s stock in a transaction that occurred on Tuesday, July 30th. The was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 8.76% of the company’s stock.

Institutional Trading of Supernus Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in Supernus Pharmaceuticals by 2.3% in the fourth quarter. Vanguard Group Inc. now owns 6,214,731 shares of the specialty pharmaceutical company’s stock worth $179,854,000 after acquiring an additional 142,551 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Supernus Pharmaceuticals by 6.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,456,369 shares of the specialty pharmaceutical company’s stock worth $71,089,000 after acquiring an additional 141,586 shares in the last quarter. Stephens Investment Management Group LLC grew its position in Supernus Pharmaceuticals by 11.7% in the fourth quarter. Stephens Investment Management Group LLC now owns 1,904,864 shares of the specialty pharmaceutical company’s stock worth $55,127,000 after acquiring an additional 200,166 shares in the last quarter. Congress Asset Management Co. MA boosted its holdings in shares of Supernus Pharmaceuticals by 12.1% during the 1st quarter. Congress Asset Management Co. MA now owns 1,032,141 shares of the specialty pharmaceutical company’s stock worth $35,206,000 after buying an additional 111,333 shares during the period. Finally, Victory Capital Management Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 13.5% during the 2nd quarter. Victory Capital Management Inc. now owns 735,038 shares of the specialty pharmaceutical company’s stock worth $19,662,000 after buying an additional 87,200 shares during the period.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.